All In Biotech

Drug Trial Radar · NCT00230217

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

Evaluation of Single Agent Rasburicase in Treatment/Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Adult and Pediatric Patients With Lymphoma/Leukemia/Solid Tumor Malignancies at Their First Relapse or Refractory Disease

Last checked: Nov 20, 2026Latest source record: Mar 30, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

94

Actual

Start

Mar 2004

Primary completion

Jul 2006

Study completion Jul 2006

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Sep 30, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center study with 2 arms. The primary objective is to assess the response to treatment with rasburicase in 2 populations of adult and pediatric patients with lymphoma/leukemia/solid tumor malignancies, those previously treated with a uricolytic agent, and those not previously treated with a uricolytic agent at their first relapse or refractory disease.

Conditions

  • Tumors
  • Hyperuricemia
  • Tumor Lysis Syndrome

Interventions

  • Rasburicase (SR29142)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Positive response based on plasma uric acid levels.Time frame: up to 48 hours after last administration.

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Alta Bates Comprehensive Cancer Center

    Berkley, California

  • Rocky Mountain Cancer Center

    Denver, Colorado

  • University of Florida Health Science Center at Jacksonville

    Jacksonville, Florida

  • New York Medical College

    Valhalla, New York

  • University of Oklahoma HSC

    Oklahoma City, Oklahoma

  • University of Pennsylvania Health Systems

    Philadelphia, Pennsylvania

  • Mary Babb Randolph Cancer Center

    Morgantown, West Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.